Prices, profits, and innovation: Examining criticisms of new psychotropic drugs' value

Health Affairs

Volumn 25, Issue 3, 2006, Pages 635-646

  Huskamp, Haiden A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; PSYCHOTROPIC AGENT;

DRUG COST; DRUG INDUSTRY; ECONOMIC ASPECT; ECONOMICS; HEALTH CARE COST; HUMAN; MARKETING; PATENT; REGRESSION ANALYSIS; REVIEW; STATISTICS; UNITED STATES;

DRUG COSTS; DRUG INDUSTRY; DRUGS, GENERIC; ECONOMIC COMPETITION; HEALTH CARE SECTOR; HUMANS; MARKETING; PATENTS; PATENTS AS TOPIC; PSYCHOTROPIC DRUGS; REGRESSION ANALYSIS; UNITED STATES;

EID: 33744718115     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.25.3.635     Document Type: Review

References (47)

1. Henry J. Kaiser Family Foundation, Trends and Indicators in the Changing Health Care Marketplace, Pub. no. 7031, Section 1, Exhibit 1.21, 8 February 2006, http://www.kff.org/insurance/7031/index.cfm (accessed 22 March 2006).
2. C. Smith et al., "Health Spending Growth Slows in 2003," Health Affairs 24, no. 1 (2005): 185-194.
3. See, for example, M. Angell, The Truth about Drug Companies: How They Deceive Us and What to Do about It (New York: Random House, 2004);
4. A.W. Mathews, "Ghost Story: At Medical Journals, Writers Paid by Industry Play Big Role," Wall Street Journal, 13 December 2005;
5. and "Eli Lilly to Pay $36 Million Fine," Wall Street Journal, 22 December 2005.
6. A. Berenson, "Big Drug Makers See Sales Decline with Their Image," New York Times, 14 November 2005;
7. and G. Critser, "Take Your Pills, Ignore Your Belly," Los Angeles Times, 20 November 2005.
8. S.H. Zuvekas, "Prescription Drugs and the Changing Patterns of Treatment for Mental Disorders, 1996-2001," Health Affairs 24, no. 1 (2005): 195-205.
9. Angell, The Truth about Drug Companies.
10. K.R. DeVault and D.O. Castell, "Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease: The Practice Parameters Committee of the American College of Gastroenterology," American Journal of Gastroenterology 94, no. 6 (1999): 1434-1442.
11. See, for example, A.J. Rush and D.J. Kupfer, "Strategies and Tactics in the Treatment of Depression," in Treatments of Psychiatric Disorders, ed. G.O. Gabbard (Washington: American Psychiatric Publishing, 2001), 1427-1428;
12. and B.J. Materson et al., "Single-Drug Therapy for Hypertension in Men: A Comparison of Six Antihypertensive Agents with Placebo," New England Journal of Medicine 328, no. 13 (1993): 914-921.
13. G. Simon, "Choosing a First-Line Antidepressant: Equal on Average Does Not Mean Equal for Everyone," Journal of the American Medical Association 286, no. 23 (2001): 3003-3004.
14. W.J. Burke, I. Gergel, and A. Bose, "Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients," Journal of Clinical Psychiatry 63, no. 4 (2002): 331-336.
15. Congressional Budget Office, How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry, July 1998, http://www.cbo.gov/showdoc.cfm?index=655&sequence=0 (accessed 15 February 2006).
16. J.Z. Lu and W.S. Comanor, "Strategic Pricing of New Pharmaceuticals," Review of Economics and Statistics 80, no. 1 (1998): 108-118.
17. CBO, How Increased Competition.
18. H.A. Huskamp, "Managing Psychotropic Drug Costs: Will Formularies Work?" Health Affairs 22, no. 5 (2003): 84-96.
19. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, "CDER Drug and Biologic Approval Reports" (see NME and NDA Approvals), 1 December 2005, http://www.fda.gov/cder/rdmt (accessed 14 February 2006).
20. I do not include NDAs for drugs with indications for Alzheimer's disease.
21. R.G. Frank, "New Estimates of Drug Development Costs" (Editorial), Journal of Health Economics 22, no. 2 (2003): 325-330.
22. Based on author's calculations from IMS Health data on antidepressant sales.
23. For example, see E. Pringle, "Why Are Atypical Drug Users Angry?" Online Journal, 19 August 2005, http://www.onlinejournal.com/ health/081905Pringle/081905pringle.html (accessed 19 December 2005).
24. R. Freedman, "The Choice of Antipsychotic Drugs for Schizophrenia" (Editorial), New England Journal of Medicine 353, no. 12 (2005): 1286-1288.
25. The first atypical, clozapine, was introduced in the 1970s. Because clozapine can result in agranulocytosis, its use is typically limited to patients whose symptoms are resistant to other treatments.
26. I used retail prices from http://www.drugstore.com for the lower end of the usual effective dose range from the 2004 Tarascon Pocket Pharmacopoeia.
27. Zuvekas, "Prescription Drugs."
28. For example, R.A. Rosenheck, "Effectiveness versus Efficacy of Second-Generation Antipsychotics: Haloperidol without Anticholinergics as a Comparator," Psychiatric Services 56, no. 1 (2005): 85-92;
29. and J.M. Davis, N. Chen, and I.D. Glick, "A Meta-Analysis of the Efficacy of Second-Generation Antipsychotics," Archives of General Psychiatry 60, no. 6 (2003): 553-564.
30. J.A. Lieberman et al., "Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia," New England Journal of Medicine 353, no. 12 (2005): 1209-1223.
31. P.S. Wang et al., "Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications," New England Journal of Medicine 353, no. 22 (2005): 2335-2341.
32. U.S. Federal Trade Commission, Generic Drug Entry Prior to Patent Expiration: An FTC Study (Washington: FTC, July 2002).
33. W.H. Schact and J.R. Thomas, The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents (Washington: Congressional Research Service, 5 January 2004).
34. Public Citizen, "2002 Drug Industry Profits: Hefty Pharmaceutical Company Margins Dwarf Other Industries," June 2003, http://www.citizen.org/ documents/Pharma_Report.pdf (accessed 13 February 2006).
35. U.S. Government Accountability Office, Prescription Drugs: FDA Oversight of Direct-to-Consumer Advertising Has Limitations (Washington: GAO, 2002).
36. A.F. Holmer, "Direct-to-Consumer Advertising - Strengthening Our Health Care System" (Letter), New England Journal of Medicine 346, no. 7 (2002): 526-528.
37. C. Rados, "Truth in Advertising: Rx Drug Ads Come of Age," FDA Consumer 38, no. 4 (2004): 20-27.
38. GAO, Prescription Drugs.
39. J.S. Weissman et al., "Consumers' Reports on the Health Effects of Direct-to-Consumer Drug Advertising," Health Affairs 22 (2003): w82-w95 (published online 26 February 2003; 10.1377/hlthaff.w3.82).
40. J.S. Weissman et al., "Physicians Report on Patient Encounters Involving Direct-to-Consumer Advertising," Health Affairs 23 (2004): w219-w233 (published online 28 April 2004; 10.1377/hlthaff.w4.219);
41. and C. Lewis, "The Impact of Direct-to-Consumer Advertising," FDA Consumer 37, no. 2 (2003): 8.
42. National Institute of Health Care Management Research and Educational Foundation, Prescription Drugs and Mass Media Advertising (Washington: NIHCM, 2000).
43. J.M. Donohue et al., "Effects of Pharmaceutical Promotion on Adherence to the Treatment Guidelines for Depression," Medical Care 42, no. 12 (2004): 1176-1185.
44. R.L. Kravitz et al., "Influence of Patients' Requests for Direct-to-Consumer Advertised Antidepressants: A Randomized Controlled Trial," Journal of the American Medical Association 293, no. 16 (2005): 1995-2002.
45. M.G. Duggan, "Does Medicaid Pay Too Much for Prescription Drugs? A Case Study of Atypical Antipsychotics," National Bureau of Economic Research Working Paper 9626, April 2003, http://www.nber.org/papers/w9626 (accessed 21 March 2006);
46. and Zuvekas, "Prescription Drugs."
47. J.S. Crowley, D. Ashner, and L. Elam, State Medicaid Outpatient Prescription Drug Policies: Findings from a National Survey, 2005 Update, Pub. no. 7381, October 2005, http://www.kff.org/medicaid/7381.cfm (accessed 13 February 2006).